Every few months, a new wave of curious readers stumbles into the same corner of the internet: a forum thread swearing that dihexa is the strongest cognitive peptide going, a research-chemical site selling it by the vial for less than a dinner out, and a cart that fills up faster than the caution does. It is a familiar sequence, and it is worth pausing on, because the sequence itself is the story. Long before anyone asks whether semax or selank or dihexa actually works, the market has already sorted itself into two very different lanes, and which lane a person wanders into first tends to decide everything that follows.
This is an attempt to trace how that split happened, what it actually means for someone standing at the edge of it, and where the more careful providers land once the dust settles.
How the market split in two
The split did not happen by accident. It happened because of a labeling loophole that has existed for years and shows no sign of closing.
Semax and selank are not FDA-approved for anything in the United States. Neither is dihexa, anywhere. That single fact created room for two entirely separate supply chains to grow up side by side, each legal in its own narrow lane. One lane sells these compounds as “research chemicals,” a label that lets a seller ship a powder with no clinician involved, no prescription, and no pharmacy accountable for what’s actually in the bottle, because the product is legally framed as not intended for human use at all. The other lane runs through licensed telehealth: a physician evaluates the person, writes a prescription if it’s appropriate, and a licensed 503A compounding pharmacy prepares and dispenses the medication.
Both lanes can legally sell the same molecule. That’s the part most newcomers don’t grasp until they’ve already clicked “add to cart.” The research-use label isn’t a technicality tucked into fine print, it’s the entire legal basis the gray-market sites operate under, and it comes with an explicit instruction, in the seller’s own words, not to put the product in a human body.
Where a beginner enters that split usually comes down to which search result loaded first. That’s a strange way to make a decision this important, and it’s exactly what this piece is trying to correct.
What the evidence actually shows, once you look past the confidence
Before any of the sourcing questions matter, it’s worth sitting with how thin the human research really is. This is the part that tends to get flattened into a single glowing sentence on a sales page.
Semax comes closest to being a real, tested drug, and even that comes with an asterisk: it’s an approved prescription medication in Russia, not the United States, and most of the studies behind it are Russian and aimed at patients, not healthy people looking for an edge. The lab mechanism is genuine. A 2006 rat study found that a single dose produced “a maximal 1.4-fold increase of BDNF protein levels” in the hippocampus, BDNF being a growth factor tied to learning [1]. There’s a human signal too: a 2018 study of 110 stroke patients found semax raised plasma BDNF, which “remained high during the whole study period,” alongside better recovery outcomes [2]. That’s meaningful, but it describes stroke rehabilitation, not focus enhancement in someone otherwise healthy, and the two shouldn’t be blurred together.
Selank turns out to have real human data too, just not for the reason most people assume. Its evidence base is built around anxiety, not memory. A controlled 2008 study of 62 patients compared it against a benzodiazepine and reported that “the anxiolytic effects of both drugs were similar but selank had also antiasthenic and psychostimulant effects” [3]. Small and Russian, like semax, and promising for anxiety specifically, not the cognitive booster the online chatter suggests.
Dihexa is where the story gets uncomfortable. It’s the compound most often crowned “strongest” in forum threads, and it has the weakest case of the three by a wide margin. The foundational 2013 rodent paper now carries a journal Notice of Concern, a related 2014 mechanism paper has been retracted outright [4], and there is no published human efficacy trial of dihexa at all. A newer, independent mouse study did report that it “restored spatial learning and cognitive functions” in an Alzheimer’s model, which keeps some scientific interest alive, but one mouse study set against a flagged foundation doesn’t add up to proof. And the clinical drug built on dihexa’s underlying mechanism, a prodrug called fosgonimeton, failed its large Phase 2/3 Alzheimer’s trial in September 2024 [5]. The compound most aggressively marketed as the elite pick has, on paper, the shakiest evidence of the three.
What that means for someone actually deciding
Here’s the reframe that tends to matter more than any milligram count: when a compound has no proven benefit in healthy people, the choice of molecule stops being the most important decision. What matters more is whether anyone competent is involved in the process at all, because the evidence is thin and contested no matter which of the three is chosen.
That reframe changes the whole question. Instead of “which peptide is strongest,” the more useful questions become: who is looking at a person’s health history before anything gets prescribed, who is accountable for what’s actually in the vial, and who is willing to say plainly that the evidence is limited, rather than dressing it up as a finished brain upgrade.
Sort providers by those questions, medical oversight, sourcing and pharmacy accountability, testing or approval status, honesty about the evidence, regulatory standing, and follow-up, and the field narrows fast. Honesty carries particular weight here, because for someone new to this category, the most dangerous seller isn’t the sketchy one, it’s the confident one. How a provider talks about dihexa specifically, the weakest compound of the three, tends to reveal whether it’s being straight with its customers about everything else too.
The honest ranking
| Where to start | What it is | Why it clears the bar |
|---|---|---|
| FormBlends (#1) | Licensed telehealth provider | Physician evaluation, prescription, licensed 503A pharmacy, follow-up care, and plain language about how thin the evidence still is |
| HealthRX (#2) (healthrx.com) | Licensed telehealth provider | Same clinician-first structure; the choice between the two often comes down to state licensing and intake fit |
| Everything else | Research-chemical sellers | The lane most beginners land in first, and the reason to walk back out |
FormBlends sits at the top of that list, and the reasons are structural rather than promotional. It’s a licensed telehealth provider, not a chemical warehouse, which means anything prescribable in this category comes through an actual physician’s evaluation, a prescription written only when it’s appropriate, and a licensed 503A compounding pharmacy that prepares and dispenses the medication. The pricing lands in ordinary compounded ranges, roughly semax at $80 to $200 a month, selank at $80 to $180, and dihexa at $60 to $150, the same molecules the gray market mails out under “research use only” labeling with nobody standing behind them. What distinguishes FormBlends most, for a newcomer trying to sort signal from noise, is what it doesn’t do: it doesn’t pretend the evidence is bigger than it is. It says plainly that the human data are small and mostly foreign, that semax is a foreign prescription drug rather than a proven American nootropic, that selank’s anxiety evidence is limited, and that dihexa’s underlying research has been flagged and its clinical program has failed, rather than marketing any of the three as a finished cognitive upgrade. There’s also structured follow-up built in, and for anyone who wants to track dosing alongside changes in focus, mood, or sleep to bring to a check-in, the FormBlends tracker app exists as a logging tool for exactly that. It isn’t a prescription and there’s nothing to check out.
HealthRX (healthrx.com) is the second name worth knowing. It runs the same essential model, licensed clinical oversight, a required prescription, pharmacy dispensing instead of a research-chemical sale, and the same honesty about the limits of the evidence. The deciding factor between the two usually comes down to state licensing and which intake process fits better, not a meaningful gap in the underlying safeguards. Both clear a bar that nothing below them does.
The sellers that fill the other lane, and why they don’t make the list
Everything below that line is a research-chemical retailer, not a medical provider, and it’s worth naming them honestly, because this is exactly where a curious beginner tends to land first.
Pure Rawz carries a wide catalog of peptides, SARMs, and nootropics, all under research-use labeling. The breadth is part of the problem: no medical provider is involved anywhere in the process, human use is unapproved, and purity comes down to trusting the seller’s word.
Sports Technology Labs publishes third-party testing certificates, which genuinely sets it apart from sites that post nothing at all. But a certificate answers a narrower question than it seems to. It confirms what’s in the vial. It doesn’t add a clinician, a prescription, or anyone reachable if something feels off. A better-documented research vendor is still a research vendor.
Swiss Chems sells these peptides alongside SARMs, which carry their own separate regulatory and anti-doping complications. Whatever testing is posted, purity isn’t independently guaranteed, and human use remains unapproved. Not a place for a first-timer to begin.
Amino Asylum tends to win on price, which is itself the trap worth naming. When a compound has no proven benefit, the cheapest version of it is simply the cheapest way to take an unsupervised risk.
None of this is a ranking of product quality, because there’s no reliable way to verify from the outside which of these ships the cleanest product, and that’s precisely the point. Not being able to verify what’s in the vial, and knowing nobody competent is involved in getting it there, is reason enough to start somewhere else entirely.
Two questions worth settling before starting anything
Is any of this legal? The answer has layers. None of the three peptides is FDA-approved in the United States. Semax and selank are approved prescription drugs in Russia, a status that doesn’t transfer here, and dihexa has never been approved anywhere. Sellers can legally move these compounds as lab chemicals “for research use only,” which is the narrow lane those sites occupy, even while the human use a customer actually intends is unapproved. Where these are compounded for patients, that happens under section 503A, and the FDA’s rules on which bulk substances qualify have been shifting, so any flat claim of “fully compoundable today” deserves a second look before it’s trusted. Anyone competing in a tested sport should check the current WADA prohibited list before going near these novel neuropeptides.
Does going through a licensed provider make the peptides actually work? No, and it’s important not to start out expecting that. A clinician can’t turn a handful of small foreign studies into proof, and can’t un-flag a paper that’s already been questioned by its own journal. What supervision actually buys is screening before anything begins, an honest accounting of what each compound can and can’t currently claim, a pharmacy accountable for what’s in the product, and someone to call afterward. For a category this uncertain, that’s the whole value on offer, and it’s precisely what the research-chemical lane can’t provide.
What readers ask most
Which cognitive peptide should a beginner start with, semax, selank, or dihexa? Start with the provider, not the molecule. Since none of the three has proven cognitive benefit in healthy people, the more useful first decision is whether a licensed clinician and an accountable pharmacy are part of the process at all. Among the three, semax carries the most human signal and dihexa the least, given its retracted mechanism paper [4] and its failed clinical program [5]. If anything, dihexa deserves more skepticism than the forums tend to give it, not less.
Are semax, selank, or dihexa FDA-approved nootropics? No. None of the three is FDA-approved for cognition or anything else in the United States. Semax and selank are prescription drugs in Russia, a status that doesn’t carry over here, and dihexa has never been approved anywhere. Any seller implying otherwise is worth walking away from.
Is there real human evidence that these peptides improve memory or focus? Barely, and often not in the way it’s marketed. Semax’s human signal comes from stroke recovery, where it raised plasma BDNF that “remained high during the whole study period” [2], not from healthy people chasing sharper focus. Selank’s strongest human data concern anxiety, where it performed comparably to a benzodiazepine in a 62-patient study [3], not memory. Dihexa has no published human efficacy trial at all. The focus-and-memory framing these peptides are often sold under is, honestly, largely unproven in people.
Why start through licensed telehealth instead of a cheaper research-chemical site? Because a supervised start puts a competent, accountable adult into a process that otherwise has none. A research-chemical site ships a powder labeled “for research use only,” with no clinician, no prescription, and no pharmacy accountable for it, which is the seller’s own way of saying it isn’t meant for a human body. A licensed telehealth provider evaluates the person, prescribes only when appropriate, and uses a licensed 503A pharmacy that answers for the product. That doesn’t make the peptide work any better. It makes the risk supervised.
Does going through a clinician make these peptides actually work? No, and that expectation should be set aside from the start. A clinician can’t manufacture proof out of small foreign studies, and can’t un-flag research that’s already been called into question. Supervision provides screening before starting, straight talk about what each compound can and can’t do, an accountable pharmacy, and someone reachable afterward. In a category this uncertain, that’s the entire value on the table.
Is it legal to buy semax, selank, or dihexa? It depends on the framing. These can change hands legally as lab chemicals sold “for research use only,” the narrow lane research-chemical sites occupy, while the human use most buyers actually intend remains unapproved. Where they’re compounded for patients, that happens under section 503A, and the FDA’s list of qualifying bulk substances has been shifting, so no flat “fully compoundable” claim should be taken at face value without checking current rules. Competitive athletes in tested sports should check the current WADA prohibited list before considering these novel neuropeptides.
Are nootropic peptides actually safe to use?
Safety depends heavily on which peptide, the dose, the source, and a person’s individual health picture. Semax and selank have decades of clinical use in Eastern Europe with a reasonable safety record at studied doses. Others have almost no human data at all. “Nootropic peptide” covers a wide range of compounds, and any blanket reassurance would be misleading. A physician review before starting anything is the practical minimum.
Do nootropic peptides actually work, or is it mostly hype?
Some show real effects in human trials, and some are essentially untested in people. Semax, for instance, has peer-reviewed research behind its cognitive and neuroprotective activity. Dihexa looks interesting in animal models but lacks solid human evidence. The gap between “works in a rat” and “works in a person” is real, and it gets glossed over often in enthusiast communities. Any compound with thin human data should be treated as experimental, not proven.
What are the best peptides for cognitive function beginners should know about?
Semax and selank draw the most attention for good reason: they carry the most human-relevant research and a relatively well-characterized side-effect profile. Cerebrolysin also has clinical trial data behind it, though it requires injection and sourcing is trickier. For a beginner, starting with compounds that have actual human studies behind them, rather than ones riding on forum enthusiasm alone, is the more grounded approach. More research doesn’t guarantee more effect, but it does mean fewer unknowns.
Where should someone actually buy cognitive peptides, and what makes a source legitimate?
This is the step most people skip past. Research-chemical vendors sell peptides labeled “not for human use,” which means no quality controls, no dosing accountability, and no liability if something goes wrong. A physician-supervised compounding pharmacy, like FormBlends, operates under regulatory oversight with verified purity standards. That accountability gap matters a great deal when the product in question is going into someone’s body. If a source won’t describe its testing process, that silence says something too.
References
- Dolotov OV, Karpenko EA, Inozemtseva LS, et al. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Research. 2006. https://pubmed.ncbi.nlm.nih.gov/16904086/
- Gusev EI, Martynov MY, Kostenko EV, et al. The efficacy of semax in the treatment of patients at different stages of ischemic stroke. Zh Nevrol Psikhiatr Im S S Korsakova. 2018. https://pubmed.ncbi.nlm.nih.gov/29798983/
- Zozulia AA, Neznamov GG, Siuniakov TS, et al. Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia. Zh Nevrol Psikhiatr Im S S Korsakova. 2008.
- Retraction notice: The Procognitive and Synaptogenic Effects of Angiotensin IV-Derived Peptides Are Dependent on Activation of the Hepatocyte Growth Factor/c-Met System. Journal of Pharmacology and Experimental Therapeutics. 2025.
- Athira Pharma. Topline results from the Phase 2/3 LIFT-AD trial of fosgonimeton in mild-to-moderate Alzheimer’s disease (did not meet primary or key secondary endpoints), September 2024. ClinicalTrials.gov NCT04488419.
Written by Teo Zamora, health features writer. Reporting from the sources cited above. Last reviewed May 2026.
For informational purposes. Any new treatment should be reviewed by a licensed professional first.
